Relmada Therapeutics (RLMD) Competitors $1.66 +0.30 (+21.53%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RLMD vs. CLLS, CRDF, FBRX, HURA, CHRS, BHST, IKT, ACOG, ZURA, and CABAShould you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include Cellectis (CLLS), Cardiff Oncology (CRDF), Forte Biosciences (FBRX), TuHURA Biosciences (HURA), Coherus Oncology (CHRS), BioHarvest Sciences (BHST), Inhibikase Therapeutics (IKT), Alpha Cognition (ACOG), Zura Bio (ZURA), and Cabaletta Bio (CABA). These companies are all part of the "pharmaceutical products" industry. Relmada Therapeutics vs. Its Competitors Cellectis Cardiff Oncology Forte Biosciences TuHURA Biosciences Coherus Oncology BioHarvest Sciences Inhibikase Therapeutics Alpha Cognition Zura Bio Cabaletta Bio Relmada Therapeutics (NASDAQ:RLMD) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations. Which has stronger valuation and earnings, RLMD or CLLS? Cellectis has higher revenue and earnings than Relmada Therapeutics. Cellectis is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelmada TherapeuticsN/AN/A-$79.98M-$2.22-0.75Cellectis$49.22M2.98-$36.76M-$0.82-3.22 Does the media prefer RLMD or CLLS? In the previous week, Cellectis had 1 more articles in the media than Relmada Therapeutics. MarketBeat recorded 4 mentions for Cellectis and 3 mentions for Relmada Therapeutics. Cellectis' average media sentiment score of 0.17 beat Relmada Therapeutics' score of -0.44 indicating that Cellectis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cellectis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is RLMD or CLLS more profitable? Relmada Therapeutics has a net margin of 0.00% compared to Cellectis' net margin of -100.69%. Cellectis' return on equity of -68.05% beat Relmada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relmada TherapeuticsN/A -223.17% -180.41% Cellectis -100.69%-68.05%-21.53% Do insiders & institutionals believe in RLMD or CLLS? 45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 20.7% of Relmada Therapeutics shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, RLMD or CLLS? Relmada Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.03, suggesting that its share price is 203% more volatile than the S&P 500. Do analysts rate RLMD or CLLS? Relmada Therapeutics currently has a consensus target price of $5.00, indicating a potential upside of 200.30%. Cellectis has a consensus target price of $4.00, indicating a potential upside of 51.52%. Given Relmada Therapeutics' higher probable upside, research analysts clearly believe Relmada Therapeutics is more favorable than Cellectis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Cellectis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCellectis beats Relmada Therapeutics on 10 of the 14 factors compared between the two stocks. Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLMD vs. The Competition Export to ExcelMetricRelmada TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.26M$2.64B$5.77B$9.91BDividend YieldN/A49.35%6.67%4.51%P/E Ratio-0.7523.3175.7426.65Price / SalesN/A740.37557.21121.56Price / CashN/A169.7737.1158.92Price / Book1.415.4611.446.07Net Income-$79.98M$32.95M$3.28B$266.32M7 Day Performance48.66%2.15%0.63%0.06%1 Month Performance192.62%7.14%6.89%3.90%1 Year Performance-31.20%0.50%59.40%23.68% Relmada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLMDRelmada Therapeutics4.134 of 5 stars$1.67+21.5%$5.00+200.3%-46.3%$55.26MN/A-0.7510News CoverageGap DownCLLSCellectis2.5094 of 5 stars$2.57-1.2%$4.00+55.6%+14.3%$143.02M$49.22M-3.13290Short Interest ↑CRDFCardiff Oncology2.8196 of 5 stars$2.10+1.0%$10.10+381.0%-2.7%$139.70M$680K-2.4120FBRXForte Biosciences3.3603 of 5 stars$11.00-2.0%$68.00+518.2%+50.1%$136.76MN/A-0.685Options VolumeHigh Trading VolumeHURATuHURA Biosciences1.4095 of 5 stars$2.70-3.9%$12.67+369.1%N/A$135.13MN/A0.00N/ACHRSCoherus Oncology4.1678 of 5 stars$1.16-1.7%$4.68+303.7%+0.0%$134.82M$266.96M0.75330News CoverageAnalyst UpgradeGap UpBHSTBioHarvest SciencesN/A$8.18+2.8%$13.67+67.1%N/A$134.36M$25.19M-11.69N/APositive NewsGap DownIKTInhibikase Therapeutics1.7829 of 5 stars$1.80-2.2%$6.50+261.1%+26.7%$134.13MN/A-0.676ACOGAlpha Cognition2.5033 of 5 stars$8.30+3.0%$20.00+141.0%N/A$134.13MN/A-5.19N/APositive NewsZURAZura Bio2.9116 of 5 stars$2.04-3.8%$14.00+586.3%-47.6%$132.64MN/A-2.913News CoverageCABACabaletta Bio2.5888 of 5 stars$1.45-3.3%$14.43+895.1%-69.6%$132.62MN/A-0.5450News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Cellectis Alternatives Cardiff Oncology Alternatives Forte Biosciences Alternatives TuHURA Biosciences Alternatives Coherus Oncology Alternatives BioHarvest Sciences Alternatives Inhibikase Therapeutics Alternatives Alpha Cognition Alternatives Zura Bio Alternatives Cabaletta Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLMD) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLMD Stock Alerts